BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35579947)

  • 1. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer.
    Luo Y; Li Z; Kong Y; He W; Zheng H; An M; Lin Y; Zhang D; Yang J; Zhao Y; Chen C; Chen R
    J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35579947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer.
    Pirlog R; Calin GA
    J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35838046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma.
    Kong Y; Luo Y; Zheng S; Yang J; Zhang D; Zhao Y; Zheng H; An M; Lin Y; Ai L; Diao X; Lin Q; Chen C; Chen R
    Cancer Res; 2023 Sep; 83(18):3077-3094. PubMed ID: 37363990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer.
    Chen C; Zheng H; Luo Y; Kong Y; An M; Li Y; He W; Gao B; Zhao Y; Huang H; Huang J; Lin T
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33661764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SUMOylation-triggered ALIX activation modulates extracellular vesicles circTLCD4-RWDD3 to promote lymphatic metastasis of non-small cell lung cancer.
    Diao X; Guo C; Zheng H; Zhao K; Luo Y; An M; Lin Y; Chen J; Li Y; Li Y; Gao X; Zhang J; Zhou M; Bai W; Liu L; Wang G; Zhang L; He X; Zhang R; Li Z; Chen C; Li S
    Signal Transduct Target Ther; 2023 Nov; 8(1):426. PubMed ID: 37925421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer.
    Zheng S; Tian Q; Yuan Y; Sun S; Li T; Xia R; He R; Luo Y; Lin Q; Fu Z; Zhou Y; Chen R; Hu C
    J Exp Clin Cancer Res; 2023 Nov; 42(1):324. PubMed ID: 38012734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer.
    Kong Y; Li Y; Luo Y; Zhu J; Zheng H; Gao B; Guo X; Li Z; Chen R; Chen C
    Mol Cancer; 2020 May; 19(1):82. PubMed ID: 32366257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precise and efficient silencing of mutant Kras
    Jiang W; Li H; Liu X; Zhang J; Zhang W; Li T; Liu L; Yu X
    Theranostics; 2020; 10(25):11507-11519. PubMed ID: 33052229
    [No Abstract]   [Full Text] [Related]  

  • 9. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
    Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
    PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KrasG12D-LOH promotes malignant biological behavior and energy metabolism of pancreatic ductal adenocarcinoma cells through the mTOR signaling pathway.
    Shen X; Chang LG; Hu MY; Yan D; Zhou LN; Ma Y; Ling SK; Fu YQ; Zhang SY; Kong B; Huang PL
    Neoplasma; 2018; 65(1):81-88. PubMed ID: 29322792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.
    Garcia MN; Grasso D; Lopez-Millan MB; Hamidi T; Loncle C; Tomasini R; Lomberk G; Porteu F; Urrutia R; Iovanna JL
    J Clin Invest; 2014 Nov; 124(11):4709-22. PubMed ID: 25250570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Extracellular Vesicle VEGF-C-mediated Lymphangiogenesis and Pancreatic Cancer Early Dissemination By a Selective HDAC1/2 Inhibitor.
    Wang CA; Li CF; Huang RC; Li YH; Liou JP; Tsai SJ
    Mol Cancer Ther; 2021 Sep; 20(9):1550-1560. PubMed ID: 34210825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; CaƱamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SUMOylation-Driven mRNA Circularization Enhances Translation and Promotes Lymphatic Metastasis of Bladder Cancer.
    Zhao Y; Chen J; Zheng H; Luo Y; An M; Lin Y; Pang M; Li Y; Kong Y; He W; Lin T; Chen C
    Cancer Res; 2024 Feb; 84(3):434-448. PubMed ID: 37991737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
    Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
    Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.
    Chen SJ; Chen YT; Zeng LJ; Zhang QB; Lian GD; Li JJ; Yang KG; Huang CM; Li YQ; Chu ZH; Huang KH
    Tumour Biol; 2016 Aug; 37(8):11299-309. PubMed ID: 26951514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
    Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
    Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.
    Kumarasamy V; Wang J; Frangou C; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
    Cancer Res; 2024 Apr; 84(7):1115-1132. PubMed ID: 38294344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
    Liao J; Chung YT; Yang AL; Zhang M; Li H; Zhang W; Yan L; Yang GY
    Mol Carcinog; 2013 Sep; 52(9):739-50. PubMed ID: 22549877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.